Hong Kong Banks Stock News

Leadership changes at China Oilfield Services and why they matter to investors China Oilfield Services (SEHK:2883) is back in focus after shareholders approved key leadership changes at a July 29, 2026 extraordinary general meeting, drawing attention to governance and the company’s long term direction. The company elected Party Secretary and CEO Liu Jianzhong as Executive Director, Chairman and member of the Nomination Committee, while President and Deputy Party Secretary Shang Jie was...

Why Swire Pacific’s Latest Earnings Matter For Investors Swire Pacific (SEHK:19) has drawn fresh attention after reporting half year 2026 results, with sales of HK$49,446 million and net income of HK$6,769 million compared with HK$45,774 million and HK$815 million a year earlier. See our latest analysis for Swire Pacific. Swire Pacific’s recent half year 2026 earnings announcement appears to have coincided with building momentum in the stock, with the share price at HK$102.1 and a year to...

In August 2026, InnoCare Pharma announced that its BTK inhibitor orelabrutinib, combined with BCL2 inhibitor mesutoclax, received Breakthrough Therapy Designation from China’s CDE for previously treated marginal zone lymphoma, following clinical data showing a 100% overall response rate and a favorable safety profile. This recognition, alongside earlier positive Phase III results for TYK2 inhibitor fadeucravacitinib in moderate-to-severe plaque psoriasis, underscores InnoCare’s push to...

Techtronic Industries (SEHK:669) has drawn fresh attention after reporting half year 2026 earnings alongside progress on its share buyback program, giving investors new data points on sales, profitability, and capital allocation. See our latest analysis for Techtronic Industries. Techtronic Industries’ latest earnings and buyback update has coincided with strong momentum in the stock, with a 30 day share price return of 16.63% and a year to date share price return of 58.40%. The 3 year total...

Why Simcere Pharmaceutical Group Stock Is Back in Focus Simcere Pharmaceutical Group (SEHK:2096) is drawing investor attention after issuing new consolidated earnings guidance for the six months to 30 June 2026, highlighting projected year on year changes in both revenue and profit. See our latest analysis for Simcere Pharmaceutical Group. Against this earnings guidance backdrop, Simcere Pharmaceutical Group’s recent momentum has been steady, with a 30 day share price return of 2.98% and a 90...

Insiders who bought CN¥13.5m worth of Teamway International Group Holdings Limited ( HKG:1239 ) stock in the last year...

Fosun International (SEHK:656) drew fresh attention on 29 July 2026 after issuing earnings guidance that points to profit attributable to shareholders of RMB 1.5b to RMB 1.8b for the first half of 2026. See our latest analysis for Fosun International. The guidance appears to have shifted sentiment around Fosun International, with a 1-day share price return of 7.38% and a 30-day share price return of 33.60% lifting the stock to HK$5.09, even though the 1-year total shareholder return is still...

Keymed Biosciences (SEHK:2162) is back in focus after announcing that CMG901, its CLDN18.2-targeting antibody drug conjugate co developed with AstraZeneca, met primary and key secondary overall survival endpoints in a global Phase III gastric cancer trial. See our latest analysis for Keymed Biosciences. The positive CMG901 news arrives after a strong run in Keymed Biosciences, with the share price at HK$81.85 and a year to date share price return of 53.13%, while the 3 year total shareholder...

China’s decision to relax its earlier regulatory pressure on Panama following a dispute over CK Hutchison Holdings (SEHK:1) terminal concessions at the Panama Canal has refocused attention on the group’s ports and related services operations. See our latest analysis for CK Hutchison Holdings. At a share price of HK$73.25, CK Hutchison Holdings has a year to date share price return of 35.65%, while its 1 year total shareholder return of 47.68% and 3 year total shareholder return of 97.51%...

HLX43 and HLX3902 milestones put Shanghai Henlius Biotech’s pipeline in focus Shanghai Henlius Biotech (SEHK:2696) has reported fresh progress in its oncology pipeline. Regulators in China cleared a new HLX43 clinical trial in advanced solid tumours, and the first patient received HLX3902 in an early prostate cancer study. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s recent HLX43 and HLX3902 updates have arrived alongside a sharp shift in sentiment, with...

The Asian markets have been experiencing a mix of geopolitical influences and economic indicators, contributing to a complex investment landscape. In such conditions, penny stocks—despite their somewhat outdated name—remain an intriguing area for investors seeking opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer potential value and growth that may not be as readily available with larger firms. In this article, we explore three Asian penny...

Why Mongolian Mining Stock Is Back On Investors’ Radar Mongolian Mining (SEHK:975) drew fresh attention on 6 August 2026 after guiding for a turnaround to a consolidated net profit of about US$100 million to US$110 million for the first half of 2026. The company cited higher washed coking coal sales volume, improved average selling prices, and initial output from its gold mine as key drivers of the expected profit compared with a net loss of US$19.9 million a year earlier. See our latest...

HBM Holdings (SEHK:2142) has drawn fresh attention after Harbour BioMed announced two company level developments. Investors are weighing the appointment of a new president for its metabolic franchise and a collaboration with China National Pharmaceutical Group. See our latest analysis for HBM Holdings. At a share price of HK$14.19, HBM Holdings has seen strong recent momentum, with a 21.8% 1 month share price return and a 17.5% year to date share price return, while the 3 year total...

The appointment of Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer gives Ascentage Pharma Group International (SEHK:6855) dedicated leadership for global business development and ex-China commercialization. See our latest analysis for Ascentage Pharma Group International. Ascentage Pharma Group International’s recent executive appointments come as the stock shows a mixed picture, with the 7 day share price return of 7.81% and 30 day share price return of...

Swire Pacific went into this earnings day with the stock up roughly 19% over the past month and trading on a premium P/E of about 15x. That set the bar high. The headline today is that the company delivered record recurring underlying profit of about HK$7.8b in H1 2026 and lifted its interim dividend by 15%. For a long term Hong Kong conglomerate story built on property, beverages and aviation cash flows, that kind of profit and dividend combination is what moves the needle. The rest of the...

Asia Cement (China) Holdings went into this earnings print with the stock at HK$1.78, modestly up over the past month but still weaker over the past quarter. The headline from Q2 is not the top line; it is the profit squeeze. Management booked CNY1,271.1m in revenue yet still reported a net loss of CNY13.0m and a loss per share. For a heavy industrial like cement, where fixed costs are unforgiving, that shift into the red is what matters for a multi year view on margins and capacity...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see PCCW Limited...

Sunlight Real Estate Investment Trust slipped 1.9% over the past week coming into this earnings print, yet the headline story is not the share price. The trust is still posting losses on a trailing 12 month basis with earnings from continuing operations of HK$227.3 million in the red, and that is where the real tension sits for holders who bought into a steady Hong Kong retail and office income story. The expectation gap is clear. The stock trades on a rich price to sales ratio of 5.2x versus...

Swire Properties went into this earnings day with a stock that had drifted over the past quarter, down about 6% over 90 days yet up roughly 12% over the past month. The headline today is not the share price. It is the sharp rebound in profit quality. Underlying profit reached HK$4.9b in the first half and recurring underlying profit hit HK$4.7b, figures that sit in stark contrast to the recent period when a HK$3.2b one off loss weighed on reported numbers. For a developer known for premium...

TOM Group’s share price closed at HK$0.37 after the latest results, little changed over the past week, yet the earnings story is far from flat. The media stock remains loss making, with trailing 12 month net income from continuing operations in a loss of HK$81.104 million, which keeps pressure on sentiment. The real pivot for long term investors is not today’s muted price move but the gradual tightening of those losses over recent years, set against a rich P/S multiple of about 2x compared...

The market barely flinched on CLP Holdings, with the stock ending at HK$77.6 and a flat week in price terms, even as the half year told a more interesting story. H1 2026 net income reached HK$5,997m and basic earnings per share came in at HK$2.37, helped by a gain on the Jhajjar disposal. That left trailing earnings and a 12.3% net margin sitting against a valuation of 18.1x P/E. For a utility built on regulated cash flows and a 4.12% dividend yield, the real debate now sits on earnings...

Natural Beauty Bio-Technology stock came into today on a soft footing, with the share price down about 3% over the past week and about 4% over the past month. Yet the latest half year report is less about short term trading and more about a deepening profitability problem. The headline is the earnings squeeze. For H1 2026 the company reported a basic loss per share of HK$0.028586 and a loss from continuing operations of HK$57.463 million on HK$523.384 million of trailing twelve month revenue...

Pacific Basin Shipping heads into this earnings season with momentum on its side. The stock closed at HK$3.8 on 7 August, capping double digit gains over the past week and month as investors positioned for stronger dry bulk conditions. The headline from H1 2026 is clear. Net profit jumped to US$105m on revenue of about US$1.1b, helped by higher time charter equivalent rates and solid cost control. For you as a shareholder, this set of numbers is less about a one day pop and more about what...

FIH Mobile entered this earnings season with a premium tag on the stock and a reputation for a sharp earnings rebound. However, the share price slipped 1.6% over the past week heading into the print. The headline this time is not revenue; it is valuation strain. A P/E of 33.9x and a share price of HK$18.99, which sits well above a cash flow value estimate of HK$4.08, are putting real pressure on the equity story. Behind that, trailing net margin has only reached 0.8%, even after a very large...